お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:COVID-19(新型コロナウイルス感染症):疫学分析と予測(2020年11月)
市場調査レポート
商品コード
974393

COVID-19(新型コロナウイルス感染症):疫学分析と予測(2020年11月)

Coronavirus Disease 2019 (COVID-19) - Epidemiology Analysis and Forecast - November 2020

出版日: | 発行: GlobalData | ページ情報: 英文 38 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.11円
COVID-19(新型コロナウイルス感染症):疫学分析と予測(2020年11月)
出版日: 2020年11月30日
発行: GlobalData
ページ情報: 英文 38 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、COVID-19(新型コロナウイルス感染症)について調査しており、主要市場の予測および分析、2020年11月時点のCOVID-19の疫学状況などの情報を提供しています。

目次

目次

第1章 現在の疫学の状況

  • 現在の疫学状況
  • 感染国主要10ヶ国の新しい症例の動向

第2章 主要市場の予測

  • 一部の国の感染のピークと減少の予測
  • 確定100件以降の国別の1日の新規確定件数の予測

第3章 発生の継続

  • ラテンアメリカ:スタートが遅かったものの、動向が気になるところであり、ピークには至っていない。
  • インド:COVID-19急増のリスクにより今後の見通しが不透明なままである。
  • ペルー:COVID-19の拡散を抑制するための厳格なロックダウン政策はほとんど行われていない。

第4章 改善の領域

  • ニュージーランド:100日以内のCOVID-19からの解放宣言。
  • 米国:COVID-19検査の陽性率が着実に低下している。
  • インド:毎日確認されているCOVID-19の症例が急増している一方、平均致死率は比較的低い。

第5章 特別な集団

  • 少数民族グループ:英国と米国でCOVID-19で死亡する可能性が2~3倍高い・
  • CKD患者:パンデミック時のプライマリケアへのアクセスが減少するため、多くが診断されない可能性。
  • ホジキンリンパ腫患者:COVID-19が死亡リスクを高める。
  • AML:ウイルス感染によりリスクを高める可能性。

第6章 データの制限

第7章 付録

図表

List of Tables

List of Tables

  • Table 1. Current Epidemiology Situation
  • Table 2. Top 10 Infected Countries
  • Table 3. Estimated Peak Weeks and Decline to Zero New Cases Weeks for Top Infected Countries (Excluding China)​

List of Figures

List of Figures

  • Figure 1. Projections of Daily New Confirmed Cases for Select Countries, Since 100th Confirmed Case​
  • Figure 2. Poland, New Daily Cases (N), and Positive Test Rate (%), March - November 2020
  • Figure 3. Daily Confirmed Cases of COVID-19 in Japan, Men and Women, All Ages, March 26-November 9, 2020
  • Figure 4. COVID-19 Daily New Cases in the 5EU, March 1-November 12
  • Figure 5. New Daily Cases of COVID-19 and Testing Positivity Rate, France, May 19 - November 11
  • Figure 6. Daily Confirmed Cases of COVID-19 in New York City, Men and Women, All Ages
  • Figure 7. Age Distribution of Confirmed Cases of COVID-19 in Pregnant and Nonpregnant Women in the US, Ages 15-44 Years, %, 2020
  • Figure 8. UK, COVID-19 Hospitalization Number and Mortality Rate, March 1-July 3
  • Figure 9. Proportion of ARDS Cases Developing Fibrosis (%)
  • Figure 10. Cumulative Incidence of COVID-10 in General Population and in PAH/CTEPH Patients
  • Figure 11. 8MM, Diagnosed Incident Cases of Ulcerative Colitis 2019
  • Figure 12. Total prevalence of Major Depressive Disorder in the UK in 2019 versus 2020
目次
Product Code: GDHCHT213

The report covers current epidemiology situation, forecast, and analysis of COVID-19 in November 2020, including forecast for key markets.The report will be updated on a regular basis.

The report provide forecast for peak-week and return-to-normal week that will help the reader plan in this uncertain time, and highlights important populations and regions most affected by the outbreak.

Current Epidemiology Situation and Forecast

  • To date, the greatest numbers of cases and deaths have occurred in the US, India, and Brazil
  • The global case fatality rate (%) has continued to decline
  • Increasing uncertainty of infection rates renders forecasting difficult in the worst-hit countries

Region Focus

  • High positive test Rates in Poland suggest this is not the time to ease social distancing measures
  • Japan's initial COVID-19 response was not enough
  • Not enough evidence to suggest a major role of seasonality in surge of COVID-19 cases in Europe. 
  • Resurgence of COVID-19 cases in France is real as testing positivity rate continues to rise
  • Fears of second wave emerge in New York City

Special Populations:

  • Pregnant women with COVID-19 at greater risk for ICU admission but not mortality
  • COVID-19 severe complications and mortality risk is minute in school age children.

Impact on Diseases

  • COVID-19 pandemic could result in increased pulmonary fibrosis patients
  • Pulmonary arterial hypertension more likely to increase COVID-19 severity
  • Ulcerative colitis patients are at increased risk of COVID-19 infection

Scope

  • The epidemiology report covers the following areas: current epidemiology situation and forecast, outbreak analysis for key regions, impact of disease on special populations, impact of COVID-19 on other diseases, and data limitations.

Reasons to Buy

  • Obtain in-depth understanding of epidemiology data for COVID-19 and analysis of up-to-date new research and insights.

Table of Contents

Table of Contents

1 Current Epidemiology Situation

  • 1.1 Current Epidemiology Situation
  • 1.2 New Cases Trend in Top 10 Infected Countries

2 Forecast for Key Markets

  • 2.1 Infection Peak and Decline Forecasts for Select Countries
  • 2.2 Projections of Daily New Confirmed Cases for Select Countries, Since 100th Confirmed Case

3 Outbreak Continues

  • 3.1 Latin America Had a Slow Start but Shows Concerning Trends, and Has Not Yet Reached Peak Cases
  • 3.2 Risk of COVID-19 Surges in India as Outlook for the Future Remains Uncertain
  • 3.3 Strict Lockdown Policies in Peru Have Done Little to Curb the Spread of COVID-19

4 Areas of Improvement

  • 4.1 New Zealand Was Declared Free of COVID-19 After Less than 100 Days
  • 4.2 Positive COVID-19 Test Rates Are Steadily Declining in the US
  • 4.3 Despite the Recent Surge in the Daily Confirmed Cases of COVID-19 in India, the Average Case Fatality Rate is Relatively Low

5. Special Populations

  • 5.1 Minority Ethnic Groups Are Two to Three Times More Likely to Die of COVID-19 in the UK and US
  • 5.2 More CKD Patients Are Likely to Go Undiagnosed Due to Reduced Primary Care Access During the Pandemic
  • 5.3 COVID-19 Increases the Risk of Mortality in Patients with Hodgkin Lymphoma
  • 5.4 Viral Infections May Increase AML Risk

6 Data Limitations

  • 6.1 There Are Drawbacks to the Available Data

7 Appendix

  • 7.1 Methodology
  • 7.2 Abbreviations
  • 7.3 Related Reports
  • 7.4 Sources
  • 7.5 About the Authors
  • 7.6 About GlobalData
  • 7.7 Contact Us
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.